US FDA is expected to lift restriction on certain peptides
March 31, 2026 — Industry News
The research peptide community received significant news today. The US Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were placed on a restricted list in 2023. This development comes directly from reports published this morning by The New York Times and Reuters, citing a senior administration official. For laboratories and researchers who rely on high-purity compounds for in-vitro studies, this potential shift could reshape access, supply chains, and compliance considerations moving forward.
At Peptide Express, we have followed regulatory updates closely since the original 2023 changes. Our existing guide on the FDA peptide ban list for 2025 already outlined the impact of those restrictions on research labs. Today's announcement represents a notable follow-up. While no formal FDA list update has been published yet, the direction appears clear: restrictions on certain peptides may soon ease. This post breaks down the background, the specific peptides involved, what the change could mean for scientific work, and how researchers can continue to source verified compounds responsibly.
Understanding the 2023 FDA Peptide Restrictions
To appreciate today's development, it helps to revisit the context from three years ago. In late 2023, the FDA reviewed nominations for bulk drug substances used in compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act. The agency placed 19 popular peptides into Category 2, a classification that signals potential significant safety risks and effectively bars traditional compounding pharmacies from producing them for patient-specific prescriptions.
Compounding pharmacies operate under strict rules designed to ensure safety and quality. When a substance lands in Category 2, pharmacies must stop preparing it unless the FDA later reclassifies it to Category 1 or approves it through a full new drug application process. The 2023 move affected a range of research-focused peptides that laboratories had been studying for years in areas such as tissue repair, metabolic regulation, and growth hormone pathways.
Researchers at the time expressed concern about disrupted supply lines. Many turned to specialized suppliers who provide compounds strictly for laboratory use. Peptide Express responded by maintaining domestic synthesis in ISO 9001-certified facilities, independent third-party HPLC and LC-MS/MS testing to 99 percent plus purity, and full Certificates of Analysis with every order. This approach kept research moving forward even as compounding options narrowed.
What Prompted Today's Expected FDA Action
The current momentum traces back to comments made by Health and Human Services Secretary Robert F. Kennedy Jr. On February 27, 2026, during an appearance on the Joe Rogan Experience podcast, Secretary Kennedy indicated that the FDA would review the status of approximately 14 peptides currently on the Category 2 list. He expressed the view that these compounds deserved a fresh look, particularly given their reported use in injury recovery and wellness applications.
According to the New York Times report published this morning, the FDA is now preparing to move forward with reclassifying more than a dozen of those restricted peptides. Reuters confirmed the same timeline and scope. The agency appears ready to allow compounding pharmacies to resume production of these injectable forms, provided they meet existing quality standards.
This shift does not represent full FDA approval for human therapeutic use. Instead, it restores the ability for licensed compounding pharmacies to prepare the compounds under physician supervision when a valid prescription exists. For the research community, the implications extend beyond clinical settings into the broader ecosystem of peptide availability and quality oversight.
Which Peptides Are Likely to See Restrictions Lifted
While the FDA has not yet released an official updated bulk substances list, industry sources and the reporting align on the expected scope. Reports indicate that 14 of the original 19 Category 2 peptides could return to allowable compounding status. Common examples frequently cited include:
- BPC-157 — widely studied for its role in tissue repair and protective mechanisms
- CJC-1295 (including blends with Ipamorelin) — a growth hormone releasing hormone analog examined in endocrine research
- Ipamorelin — researched for selective growth hormone stimulation without significant impact on cortisol or prolactin
- GHK-Cu — a copper tripeptide investigated for collagen synthesis and skin regeneration studies
- MOTS-c — a mitochondrial-derived peptide explored for metabolic homeostasis and energy regulation
- TB-500 (Thymosin Beta-4 fragment) — examined in cell migration and wound healing pathways
- Thymosin Alpha-1 — studied for immune modulation research
- AOD-9604 — researched for its potential effects on fat metabolism
- Epithalon (Epitalon) — investigated for telomere biology and cellular aging models
- KPV, Semax, Selank, and several others in the melanocortin and nootropic categories
These names match the peptides already covered in our research library guides. For instance, our full BPC-157 research guide and the MOTS-c mitochondrial mechanisms article provide detailed mechanistic overviews that remain relevant regardless of regulatory status. Researchers can cross-reference these resources when planning experiments that may benefit from improved domestic supply options.
Implications for Research Laboratories and Scientific Work
For laboratories conducting in-vitro studies, the potential lifting of restrictions carries several practical benefits. First, it could stabilize supply chains. When compounding pharmacies regain the ability to produce these peptides under controlled conditions, the overall market for high-quality research materials often experiences positive ripple effects. Greater legitimacy in one sector can encourage investment in synthesis and testing infrastructure across the board.
Second, the move underscores the importance of documentation. Even with eased compounding rules, every researcher must maintain strict adherence to intended use. At Peptide Express, all products remain designated exclusively for laboratory and in-vitro research. We continue to require buyers to affirm their professional status and research-only application. This boundary stays firm.
Third, the development highlights the value of independent verification. Whether peptides arrive through compounding pharmacies or specialized research suppliers, purity and identity testing remain non-negotiable. Our lab results page already publishes current Certificates of Analysis performed by third-party facilities using HPLC and LC-MS/MS methods. These documents include chromatograms, mass spectrometry spectra, and detailed purity data. Researchers can download batch-specific reports before placing orders, ensuring reproducibility in their protocols.
From a broader perspective, this regulatory adjustment arrives at a time when peptide research continues to expand. Our library includes recent guides on Retatrutide versus Tirzepatide versus Semaglutide comparisons, the BPC-157 plus TB-500 blend for synergistic tissue studies, and anti-aging peptide trends. These areas of investigation stand to benefit from any improvements in material availability, provided researchers select suppliers who prioritize transparency.
Potential Challenges and Considerations Moving Forward
While the news appears positive, several nuances deserve attention. The FDA has not yet issued the formal list update or Federal Register notice. Timing remains uncertain, though the senior administration official cited in today's reports suggests movement is imminent. Laboratories should monitor official FDA communications rather than relying solely on media summaries.
Even after reclassification, Category 1 status does not equal therapeutic approval. These peptides would still require physician oversight for any compounded preparations intended for human use outside research settings. For pure laboratory work, the distinction matters less, but it reinforces the need for clear separation between research compounds and clinical applications.
Another consideration involves quality consistency. Compounding pharmacies operate under USP standards and state board oversight, yet research suppliers like Peptide Express follow ISO 9001 protocols with additional third-party analytical testing. Researchers often prefer the latter for studies requiring the highest documented purity levels. The expected change does not alter our commitment to 99 percent plus HPLC verification and same-day shipping from US facilities for qualifying orders.
Edge cases also exist. Certain peptides on the original Category 2 list may not return immediately or may face additional scrutiny. For example, some reports mention that a small subset could remain restricted pending further safety data. Researchers planning long-term projects should factor in this uncertainty and maintain relationships with multiple compliant suppliers.
How Peptide Express Supports Researchers Through Regulatory Shifts
At Peptide Express, our mission has always centered on providing research-grade peptides that meet the highest laboratory standards. Today's news does not change our core operations, but it aligns with our long-standing emphasis on transparency and domestic production. Every compound in our catalog ships as lyophilized powder in sterile vials, accompanied by a Certificate of Analysis that documents independent testing results.
We continue to offer free shipping on all US orders over 150 dollars and same-day dispatch for orders placed before 2 PM EST. Bulk pricing inquiries remain available through our contact system for laboratories scaling their protocols. Our research library will update as additional FDA guidance emerges, ensuring the community stays informed.
Researchers studying compounds likely affected by this change — such as BPC-157, CJC-1295 plus Ipamorelin, or GHK-Cu — can visit our catalog today to review current stock and purity data. The lab results page already includes verified reports for many of these peptides, and we will add new batches as testing completes.
Looking Ahead: The Future of Peptide Research Access
This expected FDA action represents more than a regulatory adjustment. It signals a broader conversation about balancing innovation, safety, and access in the peptide field. For the research community, the outcome could mean fewer supply disruptions and greater confidence in material quality across sources.
Yet the fundamental principle remains unchanged: peptides sold through Peptide Express serve laboratory investigation only. We do not evaluate them for human consumption, and we strongly encourage all buyers to maintain compliance with institutional review boards and ethical research guidelines.
As the situation evolves, our team will continue monitoring developments. We encourage readers to bookmark this research section and check back for follow-up articles. In the meantime, explore our full library for in-depth guides on specific compounds, including mechanisms, study parameters, and sourcing best practices.
The peptide research landscape continues to advance rapidly. Whether through traditional compounding channels or dedicated research suppliers, the priority for scientists stays the same — reproducible results built on verified, high-purity materials. Peptide Express remains committed to supporting that standard with every order.
If you have questions about how this news might affect your specific protocols or need assistance locating Certificates of Analysis for particular batches, reach out through our contact page. Our support team operates Monday through Friday from 9 AM to 5 PM EST and responds within one business day.
Stay informed. Stay compliant. Keep advancing the science.
This article reflects information available as of March 31, 2026, based on reports from The New York Times, Reuters, and related industry sources. Official FDA guidance may provide additional details in the coming weeks. All products at Peptide Express are intended strictly for in-vitro laboratory research and are not for human or veterinary use.
Related Research Guides: